Company

Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Twelve Bio

Main focus: Treatment and diagnostics of genetic diseases

Company stage: Pre-clinical

Diseases: Undisclosed

Genome editing tool: CRISPR-Cas12a

Funding stage: Private

Location: Copenhagen, Denmark

Website: https://twelve.bio/

Twelve Bio is a pre-clinical stage gene-editing company that primarily focuses on the Cas12a enzyme. The company is located in Copenhagen, Denmark, as part of the Bioinnovation Institute accelerator, and has yet to disclose its first therapeutic programme.

Your Latest CMN News

SNIPR Biome Receives CARB-X Funding to Test...

SNIPR Biome announced today that it has secured funding from CARB-X to further advance SNIPR001 into clinical trials in haematological cancer...

CMN Weekly (19 April 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

A Secondary Checkpoint Refines CRISPR Precision

New findings highlight a secondary conformational checkpoint in CRISPR-Cas9 that significantly enhances its accuracy in gene editing.

Cancer's Weak Point Is Its Metabolism, CRISPR...

American researchers have developed a novel CRISPR-based platform to identify and characterise essential nutrient transporters that support cancer...

Next-Generation CRISPR Screening Libraries Without...

Sponsored content

Founded in 2018, Vivlion is a spin-out of Goethe University Frankfurt. Its mission is to provide innovative gene-editing reagents and screening...

CMN Weekly (12 April 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

Company: Twelve Bio

Search CRISPR Medicine